Chemical formula: C₂₃H₂₇FN₄O₃ Molecular mass: 426.484 g/mol PubChem compound: 115237
Paliperidone is a selective blocking agent of monoamine effects, whose pharmacological properties are different from that of traditional neuroleptics. Even though paliperidone is a strong D2-antagonist, which is believed to relieve the positive symptoms of schizophrenia, it causes less catalepsy and decreases motor functions to a lesser extent than traditional neuroleptics.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05AX13 | Paliperidone | N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AX Other antipsychotics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| INVEGA Prolonged-release tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| XEPLION Prolonged release suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Paliperidone is an active ingredient of these brands:
United States (US)Australia (AU)Brazil (BR)Canada (CA)Croatia (HR)Ecuador (EC)Germany (DE)Ireland (IE)New Zealand (NZ)Nigeria (NG)Poland (PL)Romania (RO)Singapore (SG)South Africa (ZA)Spain (ES)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
